

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT – FRAMEWORK AGREEMENT IN RESPECT OF FORMATION OF JOINT VENTURE

This is a voluntary announcement made by Genscript Biotech Corporation (the “**Company**”).

Pursuant to the disclosure made in the section headed “Cornerstone Investor” in the prospectus dated 17 December 2015 issued by the Company, the Company has entered into a strategic framework agreement (“**Original Framework Agreement**”) on 11 December 2015 with China Resources Strategic Investment Company Limited (“**China Resources Strategic Investment**”), a wholly-owned subsidiary of China Resources (Holdings) Company Limited (“**China Resources Group**”), pursuant to which the Company and the China Resources Strategic Investment (or through their designated affiliated companies) will conduct strategic cooperation within twelve months thereafter.

The board of directors of the Company is pleased to announce that on 29 December 2016 (after trading hour), after negotiation on friendly basis, the Company and (a) China Resources Pharmaceutical Group Limited and (b) China Resources Pharmaceutical Industry Development (Beijing) Co., Ltd. (collectively the “**China Resources Parties**”) (both of which China Resources Group is the controlling shareholder) have entered into a further framework agreement (the “**Framework Agreement**”) to elaborate certain details of the Original Framework Agreement. The strategic cooperation between the Company and the China Resources Parties would be conducting research and development of a biotechnology (the “**Project**”).

According to the Framework Agreement, (i) the Company and (ii) the core technology team and core management team of the Company will each incorporate a company with limited liability as their respective wholly-owned subsidiary in the Cayman Islands or the British Virgin Islands, together with the China Resources Parties, will incorporate a joint venture company in the Cayman Islands as the operating entity of the Project.

The Company and the China Resources Parties anticipate that a formal joint venture agreement in respect of the Project would be entered into between them by 31 January 2017 and the parties have also agreed that in the event that the said formal joint venture agreement could not be signed by 30 June 2017, the Framework Agreement would be terminated automatically. The parties shall be released from all of their obligations under the Framework Agreement and no claim shall be made by either party against the other party. The Company shall make further announcement in respect of the Project in due course in accordance with the the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited if and when required.

By Order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 29 December 2016

As at the date of this announcement, the directors of the Company are:

Executive Directors: *Dr. Zhang Fangliang, Ms. Wang Ye and
Mr. Meng Jiange*

Non-executive Directors: *Dr. Wang Luquan, Mr. Huang Zuie-Chin and
Mr. Pan Yuexin*

*Independent Non-executive
Directors:* *Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min*

* *For identification purposes only*